Liyun Huo

Nov 21, 2024 | biorxiv.org | Liyun Huo |Qin Qin |Tian Tian |Xing Zhang

AbstractThe authors have withdrawn this manuscript because of incorrect figure legends and some typos in the main text. Therefore, the authors do not wish this work to be cited as a reference for the project. If you have any questions, please contact the corresponding author. Competing Interest StatementThe authors have declared no competing interest.

Nov 18, 2024 | biorxiv.org | Liyun Huo |Qin Qin |Tian Tian |Xing Zhang

AbstractSince the outbreak of the COVID-19 pandemic in 2019, antibody-based therapies have played a key role in combating the virus. In addition to conventional antibodies, single-domain heavy-chain antibodies (nanobodies) derived from camelids have emerged as promising therapeutic candidates due to their small molecular weight, high stability, and strong binding affinity.

Oct 30, 2024 | biorxiv.org | Liyun Huo |Tian Tian |Yanqin Xu |Qin Qin

AbstractIn recent years, single-domain heavy chain antibodies (nanobodies), with only one-tenth the molecular weight of conventional antibodies, have emerged as important therapeutic proteins in the fight against SARS-CoV-2. However, the rapid mutation of the virus often renders existing nanobodies ineffective, underscoring the need to develop nanobodies that specifically target new variants.